Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
G1 Therapeutics, Inc. (Nasdaq: GTHX) is a commercial-stage oncology biopharmaceutical company committed to developing next-generation therapies to improve the lives of cancer patients. The company is based in Research Triangle Park, N.C., and leverages its proprietary kinase drug discovery platform to advance a pipeline of innovative compounds. G1's flagship product, COSELA® (trilaciclib), has been approved by the FDA to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).
In addition to COSELA, G1 Therapeutics is actively developing and evaluating trilaciclib in combination with other anti-cancer therapies. One notable project is the global, multi-center, randomized, placebo-controlled Phase 3 trial known as PRESERVE 2, which investigates trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). Preliminary results have shown promising survival benefits, indicating trilaciclib’s potential to protect bone marrow and enhance patient outcomes during cytotoxic therapy.
The company also engages in strategic partnerships to broaden its impact. For instance, G1 Therapeutics has entered agreements with companies like Pepper Bio and Jupiter Bioventures to advance the clinical development and commercialization of lerociclib, another promising CDK4/6 inhibitor. These collaborations aim to explore lerociclib's efficacy in treating various cancers, including HCC and radioprotection uses.
On the financial front, G1 Therapeutics reported revenues of $82.5 million for the full year 2023, reflecting significant growth from $51.3 million in the previous year. The company's ongoing commitment to innovation and strategic collaborations underscores its role as a key player in oncology therapeutics.
For more information, visit G1 Therapeutics and follow them on Twitter and LinkedIn.
G1 Therapeutics (Nasdaq: GTHX) announced the upcoming presentation of mature Phase 2 results on trilaciclib combined with sacituzumab govitecan (SG) at the ASCO 2024 Meeting from May 31 to June 4 in Chicago. The data indicates a positive impact on overall survival (OS) and tolerability in metastatic triple-negative breast cancer (mTNBC) compared to SG alone. The poster session detailing these findings will occur on June 2, 2024, from 9:00 AM to 12:00 PM CDT.
The abstract includes initial trial results shared in January 2024, with the new poster providing updated Phase 2 safety and efficacy outcomes.
G1 Therapeutics (Nasdaq: GTHX), a commercial-stage oncology company, announced that its Chief Medical Officer, Dr. Raj Malik, and Chief Commercial Officer, Andrew Perry, will participate in TD Cowen’s 5th Annual Oncology Innovation Summit.
The event will take place on May 29, 2024, at 8:30 AM EDT. A webcast of the fireside chat will be available on the company's Events & Presentations page.
G1 Therapeutics (Nasdaq: GTHX) and Deimos Biosciences, a Jupiter Bioventures portfolio company, announced a global licensing agreement for lerociclib, excluding the Asia-Pacific region. Lerociclib, a potent CDK4/6 inhibitor, will be developed for radioprotective uses. Jupiter Bioventures gains exclusive rights for clinical development, regulatory submissions, and commercialization in the US, Europe, Japan, and other markets excluding Asia-Pacific. G1 will receive 10% of Deimos' common stock and 20% royalties on annual net sales. The agreement aims to advance a solution in a high unmet need area.
G1 Therapeutics, Inc. announced the grant of inducement stock options and restricted stock units to a newly hired employee under the Amended and Restated 2021 Plan. The stock options are exercisable for 2,100 shares at $4.13 per share, with a ten-year term and vesting over four years. The RSUs consist of 1,050 units, vesting over four years as well. These awards were granted to induce the new employee to join G1 as per Nasdaq rules.
G1 Therapeutics reported $14.1 million in net revenue from sales of COSELA for Q1 2024, reaffirming $60-$70 million guidance for 2024. They announced updated efficacy results and final analysis from key trials. Cash runway extends to Q3 2025.
The financial results for Q1 2024 showed total revenue of $14.5 million, including $14.1 million from COSELA sales. Operating expenses decreased compared to Q1 2023. G1 reaffirmed its 2024 financial guidance of $60-$70 million in COSELA net revenue.
G1 Therapeutics, Inc. and Pepper Bio have announced a global licensing agreement for lerociclib, excluding Asia-Pacific, where Pepper Bio gains exclusive rights for clinical development, regulatory submissions, and commercialization in the US, Europe, Japan, and other global markets. Lerociclib, a selective CDK4/6 inhibitor, has shown promising efficacy in clinical studies, particularly in HR+/Her2- metastatic breast cancer and hepatocellular carcinoma. Pepper Bio's COMPASS platform identifies novel drug targets and will advance lerociclib to Phase 2 trials. G1 Therapeutics will receive mid-single-digit millions upfront and up to $135M in milestone payments, along with double-digit royalties on lerociclib sales.
FAQ
What is the current stock price of G1 Therapeutics (GTHX)?
What is the market cap of G1 Therapeutics (GTHX)?
What does G1 Therapeutics, Inc. specialize in?
What is COSELA® (trilaciclib)?
What is the PRESERVE 2 trial?
Where is G1 Therapeutics, Inc. located?
Who are G1 Therapeutics' key partners?
What recent financial achievements has G1 Therapeutics reported?
What is lerociclib?
How can I get more information about G1 Therapeutics?
What types of cancer are G1 Therapeutics’ therapies targeting?
What are G1 Therapeutics’ future goals?
